Cargando…

Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis

Sporadic lymphangioleiomyomatosis (S-LAM) is a rare lung disease characterized by the proliferation of smooth muscle-like LAM cells and progressive cystic destruction. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has a proven efficacy in patients with LAM. However, the therapeutic me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yen-Lin, Chen, Po-Ru, Lai, Ying-Ju, Hsu, Hsao-Hsun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395305/ https://www.ncbi.nlm.nih.gov/pubmed/34445268 http://dx.doi.org/10.3390/ijms22168564

Ejemplares similares

Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis
por: Aghaeimeybodi, Fatemeh, et al.
Publicado: (2019)

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis
por: Steagall, Wendy K., et al.
Publicado: (2023)

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
por: Neurohr, Claus, et al.
Publicado: (2011)

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
por: Zhan, Yongzhong, et al.
Publicado: (2018)

Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
por: Hu, Siqi, et al.
Publicado: (2019)

Sirolimus in lymphangioleiomyomatosis: A case in point for research in ‘orphan’ diseases
por: Koul, Parvaiz A, et al.
Publicado: (2019)

Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
por: Namba, Masashi, et al.
Publicado: (2017)

Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus
por: Sakaue, Takahiko, et al.
Publicado: (2018)

Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier
por: Sonobe, Shoko, et al.
Publicado: (2018)

Quantitative analysis of computed tomography of the lungs in patients with lymphangioleiomyomatosis treated with sirolimus
por: Ko, Yuki, et al.
Publicado: (2020)

Sporadic Lymphangioleiomyomatosis Disease: A Case Report
por: Nikmanesh, Yousef, et al.
Publicado: (2023)

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015)

Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report
por: Verma, Ajay Kumar, et al.
Publicado: (2018)

Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series
por: Zhou, Li, et al.
Publicado: (2018)

Probability of sporadic lymphangioleiomyomatosis in women presenting with spontaneous pneumothorax
por: Suter, Audrey, et al.
Publicado: (2023)

Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort
por: Gopalakrishnan, Vissagan, et al.
Publicado: (2018)

Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
por: Revilla-López, Eva, et al.
Publicado: (2021)

Cofilin Oligomer Formation Occurs In Vivo and Is Regulated by Cofilin Phosphorylation
por: Goyal, Pankaj, et al.
Publicado: (2013)

Gene mutations in sporadic lymphangioleiomyomatosis and genotype–phenotype correlation analysis
por: Huang, Jiannan, et al.
Publicado: (2022)

COVID-19 in a patient with sporadic lymphangioleiomyomatosis awaiting lung transplantation
por: Noda, Yoshimi, et al.
Publicado: (2021)

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis
por: Sakurai, Teiko, et al.
Publicado: (2021)

Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study
por: Cheng, Chongsheng, et al.
Publicado: (2022)

Sirolimus induced granulomatous interstitial pneumonitis
por: Ussavarungsi, Kamonpun, et al.
Publicado: (2012)

Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation
por: Davis, Richard C, et al.
Publicado: (2011)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study
por: Terraneo, Silvia, et al.
Publicado: (2021)

Does phosphorylation of cofilin affect the progression of human bladder cancer?
por: Chung, Hong, et al.
Publicado: (2013)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

Sirolimus-induced interstitial pneumonitis in a renal transplant recipient
por: Kanaan, Nada, et al.
Publicado: (2008)

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
por: Pluvy, Johan, et al.
Publicado: (2019)

Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases
por: Nishino, Koichi, et al.
Publicado: (2017)

Sporadic uterine Lymphangioleiomyomatosis (LAM): Report of a unique case arising in the lower uterine segment with short review
por: Pongsuvareeyakul, Tip, et al.
Publicado: (2021)

Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis
por: Contini, Paola, et al.
Publicado: (2011)

The phosphorylation level of Cofilin-1 is related to the pathological subtypes of gastric cancer
por: Kang, Xi, et al.
Publicado: (2022)

Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
por: Alkhunaizi, Ahmed M., et al.
Publicado: (2020)

Treatment of lymphangioleiomyomatosis and Camões
por: Rufino, Rogério
Publicado: (2015)

Methylprednisolone in the treatment of lymphangioleiomyomatosis
por: Dale, Ventour, et al.
Publicado: (2022)

Chylothorax, in the Spotlight of Lymphangioleiomyomatosis
por: Gámez-Baeza, Pablo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p363mapadhmt3tfr5pakt0en0l